Damora Therapeutics (DMRA) Operating Income Growth (3y) (2022 - 2026)
Damora Therapeutics (DMRA) Operating Income Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | 16.96% |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn | 38.78% |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn | 69.02% |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 55.96% |
| 10 | Damora Therapeutics | 1.00 Bn | 799.14 Mn | - | -31.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.69% |
| Dec 31, 2025 | -146.14% |
| Sep 30, 2025 | 38.58% |
| Jun 30, 2025 | 41.54% |
| Mar 31, 2025 | 46.46% |
| Dec 31, 2024 | 19.21% |
| Sep 30, 2024 | 33.30% |
| Jun 30, 2024 | 23.11% |
| Mar 31, 2024 | 24.90% |
| Dec 31, 2023 | 16.12% |
| Sep 30, 2023 | 5.49% |
| Jun 30, 2023 | -20.75% |
| Mar 31, 2023 | -32.27% |
| Dec 31, 2022 | -36.52% |
| Sep 30, 2022 | -68.95% |